Article · Wikipedia archive · Last revised Jun 13, 2026

Adrogolide

Adrogolide (INNTooltip International Nonproprietary Name; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride (USANTooltip United States Adopted Name) in the case of the hydrochloride salt, is a dopamine D1-like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed.

Last revised
Jun 13, 2026
Read time
≈ 1 min
Length
316 w
Citations
23
Source
Wikipedia ↗
Adrogolide
Clinical data
Other namesA-93431; ABT-431; ABT431; DAS-431; DAS431
Routes of
administration		Parenteral (e.g., intravenous, inhalation)1
Drug classDopamine D1-like receptor agonist
ATC code
  • None
Pharmacokinetic data
BioavailabilityOral: ≤4%1
Sublingual: 10–13%1
Inhalational: 82–107%1
MetabolismDeacetylation1
MetabolitesA-869291
Elimination half-life3–4 hours1
Identifiers
  • [(1S,10R)-4-acetyloxy-15-propyl-14-thia-11-azatetracyclo[8.7.0.02,7.013,17]heptadeca-2,4,6,13(17),15-pentaen-5-yl] acetate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H25NO4S
Molar mass399.51 g·mol−1
3D model (JSmol)
  • CCCC1=CC2=C(S1)CN[C@H]3[C@H]2C4=CC(=C(C=C4CC3)OC(=O)C)OC(=O)C
  • InChI=1S/C22H25NO4S/c1-4-5-15-9-17-21(28-15)11-23-18-7-6-14-8-19(26-12(2)24)20(27-13(3)25)10-16(14)22(17)18/h8-10,18,22-23H,4-7,11H2,1-3H3/t18-,22+/m1/s1
  • Key:KTEBZVJGMARTOQ-GCJKJVERSA-N

Adrogolide (INNTooltip International Nonproprietary Name; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride (USANTooltip United States Adopted Name) in the case of the hydrochloride salt, is a dopamine D1-like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed.23415

It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D1 and D5 receptor full agonist A-86929.1 The effects of adrogolide and A-86929 in animals and humans have been studied.15 Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness.1

Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences.234 It reached phase 2 clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001.234 The drug is said to have been the first extensively characterized dopamine D1 receptor full agonist.1

See also

See also

References

References

  1. Giardina WJ, Williams M (2001). "Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data". CNS Drug Rev. 7 (3): 305–316. doi:10.1111/j.1527-3458.2001.tb00201.x. PMC 6741696. PMID 11607045.
  2. "Adrogolide". AdisInsight. 30 January 2013. Retrieved 1 February 2026.
  3. "Delving into the Latest Updates on Adrogolide Hydrochloride with Synapse". Synapse. 15 November 2025. Retrieved 1 February 2026.
  4. "Adrogolide Drug Profile". Ozmosi. 1 January 1900. Retrieved 1 February 2026.
  5. Unattributed (2000). "Information Update Volume 1-24, Number 8". Drugs of the Future. 25 (8): 843–888 (844–844). ABT-431. Adrogolide Hydrochloride [...]